↓ Skip to main content

Mu Opioid Receptor Antagonists: Recent Developments

Overview of attention for article published in ChemMedChem, October 2007
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (85th percentile)
  • Good Attention Score compared to outputs of the same age and source (70th percentile)

Mentioned by

policy
1 policy source
patent
5 patents
wikipedia
1 Wikipedia page

Citations

dimensions_citation
66 Dimensions

Readers on

mendeley
97 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Mu Opioid Receptor Antagonists: Recent Developments
Published in
ChemMedChem, October 2007
DOI 10.1002/cmdc.200700143
Pubmed ID
Authors

Allan J. Goodman, Bertrand Le Bourdonnec, Roland E. Dolle

Abstract

For thousands of years mu opioid agonists such as morphine have been utilized for their analgesic properties. Today, morphine and related compounds are still used as a first line therapy in the treatment of moderate to severe pain. However, despite the clear benefits of mu agonists in pain management, severe side effects such as dependence and respiratory depression are associated with use of these drugs. To date, there are only two approved mu opioid antagonists for use in the treatment of these adverse effects, that is, naloxone and naltrexone. However, many other clinical and therapeutic areas have been linked to mu opioid receptor antagonism. These include treatment of opioid induced pruritus of the skin, obesity, and Parkinson-induced tardive dyskinesia. Currently there are two compounds, N-methylnaltrexone and alvimopan, under FDA review as possible treatments for opioid induced bowel dysfunction and postoperative ileus. These compounds are of special interest as they are peripherally restricted. This attribute enables treatment of peripheral side effects induced by opioid agonists without reversal of the centrally mediated analgesia of the agonist. In this article we discuss the structural classes of mu opioid antagonists, their potential clinical applications, and review the relevant patents of the last ten years.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 97 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Chile 2 2%
China 1 1%
Unknown 94 97%

Demographic breakdown

Readers by professional status Count As %
Student > Master 17 18%
Student > Ph. D. Student 14 14%
Researcher 10 10%
Student > Bachelor 8 8%
Student > Doctoral Student 7 7%
Other 20 21%
Unknown 21 22%
Readers by discipline Count As %
Medicine and Dentistry 21 22%
Agricultural and Biological Sciences 15 15%
Chemistry 13 13%
Biochemistry, Genetics and Molecular Biology 7 7%
Pharmacology, Toxicology and Pharmaceutical Science 6 6%
Other 14 14%
Unknown 21 22%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 April 2020.
All research outputs
#3,798,611
of 25,374,647 outputs
Outputs from ChemMedChem
#421
of 3,909 outputs
Outputs of similar age
#9,636
of 83,514 outputs
Outputs of similar age from ChemMedChem
#3
of 17 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,909 research outputs from this source. They receive a mean Attention Score of 4.1. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 83,514 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.